Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection

Micallef, Joëlle; Soeiro, Thomas; Jonville‐Béra, Annie‐Pierre

doi:10.1016/j.therap.2020.05.003

Cited by 83 publications

(81 citation statements)

References 53 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most frequent comorbidities were asthma ( n = 3), sickle cell diseases (SCD, n = 3) and overweight or obesity ( n = 3) (detailed in Table 1 ). None of them received non-steroidal anti-inflammatory drugs prior to admission [ 14 , 15 , 16 , 17 ]. Of importance, 20 (87%) patients, including 100% of the infants, cohabitated with an adult with clinical signs suggestive of a viral infection in the days prior to the onset of the symptoms of the child.…”

Section: Resultsmentioning

confidence: 99%

The Wide Spectrum of COVID-19 Clinical Presentation in Children

Nathan

Prévost

Sileo

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Ten months after its appearance in December 2019, SARS-CoV-2 has infected more than 25 million patients worldwide. Because children were first identified as potential spreaders of the virus, schools were closed in several countries. However, it rapidly became evident that the number of hospitalized children infected by SARS-CoV-2 was dramatically lower than that of adults. To date, only hypotheses have been raised to explain this difference, so it is of great importance to describe the presentation of this disease among children. Here, we describe a wide spectrum of COVID-19 manifestation in children in a dedicated pediatric unit in France. Methods: Patients hospitalized with COVID-19 who were diagnosed on the basis of either positive SARS-CoV-2 RT-PCR in nasopharyngeal swabs and/or typical aspects in chest-computed tomography (CT) were included between March and May 2020 in Paris. Results: Twenty-three patients were included on the basis of positive RT-PCR (n = 20) and/or typical aspects in CT (n = 4). The median age was 4.9 years [0.1–17.6]. Patients were grouped by age (<2 years old: n = 14, 61%; 2–10 years old: n = 2, 9%; >10 years old: n = 7, 30%). Overweight or obesity was reported in only three patients. At presentation, the most frequent symptom in the overall cohort was fever (n = 18, 78%), followed by acute rhinitis (n = 9, 64%) and cough (n = 7, 50%) in the under 2-year-old group and cough (n = 4, 57%), fatigue, dyspnea and abdominal pain (n = 3, 43% each) in the over 10-year-old group. Five patients required ICU treatment, four of whom were aged >10 years, two presented with acute myocarditis, and two were sickle cell disease patients who presented with acute chest syndrome. Discussion and conclusion: The youngest patients seem to present milder forms of COVID-19 without the need for ICU treatment and with a shorter length of hospitalization. More severe evolutions were observed in teenagers, with, however, favorable outcomes. Given the context of closed schools and confinement, the infection of these children suggests intra-familial transmission that needs to be further assessed. This description might help to understand the intriguing differences in COVID-19 severity across age-classes.

show abstract

Section: Resultsmentioning

confidence: 99%

The Wide Spectrum of COVID-19 Clinical Presentation in Children

Nathan

Prévost

Sileo

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Furthermore, it has been suggested that SARS-CoV-2 recruits the host cells autophagy pathway components for replication [ 10 ]. So, using the anti-inflammatory drugs, some antiviral drugs and autophagy inhibitors [ 11 , 12 ] as well as some renin-angiotensin enzymes inhibitors [ 13 – 15 ] are the common therapies for patients with COVID-19. However, despite many efforts to produce the vaccine or effective drugs, there is no vaccine or drug specific to eradicate this pandemic disease yet.…”

Section: Introductionmentioning

confidence: 99%

Hypoxia: A key feature of COVID-19 launching activation of HIF-1 and cytokine storm

2020

View full text Add to dashboard Cite

COVID-19, disease caused by the new coronavirus, SARS-CoV-2, appeared in the end of 2019 and was rapidly spread in most countries. This respiratory virus has different symptoms from moderate to severe, and results in lung pneumonia following acute respiratory distress syndrome (ARDS) and patient’s death in severe cases. ARDS is a severe form of acute lung injury that is caused by high inflammatory response of the innate immunity cells. Hypoxia is the common feature in the inflammatory sites with having various impacts on this condition by induction of some factors such as hypoxia inducible factor-1α (HIF-1α). HIF-1α regulates some important cellular processes including cell proliferation, metabolism and angiogenesis. Furthermore, this factor is activated during the immune responses and plays important roles in the inflammation site by inducing pro-inflammatory cytokines production through immune cells. So, in this study the possible effect of the HIF-1α on the COVID-19 pathogenesis with emphasizes on its role on innate immunity response has been discussed.

show abstract

“…Concerns with NSAIDs worsening lung infection is not new or speci c to COVID-19, in fact previous pharmacoepidemiological data, and pharmacovigilance analysis report that NSAID exposure increases the risk of severe pulmonary complications, supported by experimental data, and pharmacological plausibility. 20 These concerns and analyses were led by the French Regional Pharmacovigilance Centers possibly explaining why early alerts on ibuprofen in COVID-19 came from France.…”

Section: Discussionmentioning

confidence: 99%

Ibuprofen and NSAIDs use in COVID-19 infected patients is Not Associated with Worse Outcomes

Esba

Alqahtani

Thomas

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Ibuprofen disappeared off the pharmacy shelves during the COVID-19 pandemic. However, a while later circulating information was that ibuprofen should be avoided as it could worsen COVID-19 symptoms. The aim of our study was to assess the association of NSAID acute and chronic use with worse COVID-19 outcomes.Methods: We did a prospective cohort study between April 12 and June 1, 2020. Adults consecutively diagnosed with COVID-19 were included. Information on NSAID use was collected through a telephone questionnaire and patients were followed up for COVID-19 infection outcomes, including death, admission, severity, time to clinical improvement, oxygen requirement, and length of stay.Findings: Ibuprofen acute use was not associated with a greater risk of mortality relative to nonusers (adjusted hazard ratio (HR) 0·632 [95% CI, 0·073- 5·441; P=0·6758]). NSIAD chronic use was also not associated with greater risk of mortality (adjusted HR, 0·492 [95% CI, 0·178 - 1·362; P= 0·1721]). Ibuprofen acute use was not associated with a higher risk of admission compared to non-NSAID users (adjusted odds ratio OR, 1·271; 95% CI, 0·548 - 2·953). NSAID users did not have a significantly longer time to clinical improvement, or length of stay.Interpretation: Ibuprofen and other NSAID acute or chronic use were not associated with worse COVID-19 disease outcomes.

show abstract

Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection

Cited by 83 publications

References 53 publications

The Wide Spectrum of COVID-19 Clinical Presentation in Children

The Wide Spectrum of COVID-19 Clinical Presentation in Children

Hypoxia: A key feature of COVID-19 launching activation of HIF-1 and cytokine storm

Ibuprofen and NSAIDs use in COVID-19 infected patients is Not Associated with Worse Outcomes

Contact Info

Product

Resources

About